Vertex drugs show promise with DF508

LisaGreene

New member
<P>I am cautiously hopeful! :) Hugs, Lisa</P>
<P><A href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683"><U><FONT color=#800080>http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683</FONT></U></A></P>
 

LisaGreene

New member
<P>I am cautiously hopeful! :) Hugs, Lisa</P>
<P><A href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683"><U><FONT color=#800080>http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683</FONT></U></A></P>
 

LisaGreene

New member
<P>I am cautiously hopeful! :) Hugs, Lisa</P>
<P><BR><A href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683"><U><FONT color=#800080>http://investors.vrtx.com/releasedetail.cfm?ReleaseID=583683</FONT></U></A></P><BR>
 

scanboyd

Member
Thank you for sharing article. Hopefully it will be put on fast track through the FDA once all the testing is done. Looks like it could help<img src="i/expressions/face-icon-small-smile.gif" border="0">)!!
 

scanboyd

Member
Thank you for sharing article. Hopefully it will be put on fast track through the FDA once all the testing is done. Looks like it could help<img src="i/expressions/face-icon-small-smile.gif" border="0">)!!
 

scanboyd

Member
<BR>Thank you for sharing article. Hopefully it will be put on fast track through the FDA once all the testing is done. Looks like it could help<img src="i/expressions/face-icon-small-smile.gif" border="0">)!!
 

LouLou

New member
Let's discuss why the stock dropped 10% with this announcement?
Do you all think it's because the arm of the study that used the 150 mg of 770 didn't do well? To get the best results they had to use 809 (200 mgs) with 770 (at 250 mgs). The other study (770 alone which is in open label) is using 150 mgs. As one of my friends in pharma said...results are results though and a new drug is a new drug. When the FDA approves it the stock will rebound. Investors just don't like to see that the pharma co. doesn't know everything about a drug. Do you all think this is what caused the drop? It had to do with efficacy which I'll admit I don't totally understand in this context but this is my best guess. What do u think?
 

LouLou

New member
Let's discuss why the stock dropped 10% with this announcement?
Do you all think it's because the arm of the study that used the 150 mg of 770 didn't do well? To get the best results they had to use 809 (200 mgs) with 770 (at 250 mgs). The other study (770 alone which is in open label) is using 150 mgs. As one of my friends in pharma said...results are results though and a new drug is a new drug. When the FDA approves it the stock will rebound. Investors just don't like to see that the pharma co. doesn't know everything about a drug. Do you all think this is what caused the drop? It had to do with efficacy which I'll admit I don't totally understand in this context but this is my best guess. What do u think?
 

LouLou

New member
Let's discuss why the stock dropped 10% with this announcement?
<br />Do you all think it's because the arm of the study that used the 150 mg of 770 didn't do well? To get the best results they had to use 809 (200 mgs) with 770 (at 250 mgs). The other study (770 alone which is in open label) is using 150 mgs. As one of my friends in pharma said...results are results though and a new drug is a new drug. When the FDA approves it the stock will rebound. Investors just don't like to see that the pharma co. doesn't know everything about a drug. Do you all think this is what caused the drop? It had to do with efficacy which I'll admit I don't totally understand in this context but this is my best guess. What do u think?
 

twodogstudio2

New member
Yes I am so hopeful but that stock drop surprised me. Could the investors and financial types have misinterpreted something? From what I read they gave 770 to some people but the therapy is meant for both drugs to be used and that only happened for some in the study and only then only for one week. Seems way too early to get too up or down about it. When a large number of patients are on both drugs in high doses for an extended time then we shall see what the results are and can cry tears of joy or frustration.
 

twodogstudio2

New member
Yes I am so hopeful but that stock drop surprised me. Could the investors and financial types have misinterpreted something? From what I read they gave 770 to some people but the therapy is meant for both drugs to be used and that only happened for some in the study and only then only for one week. Seems way too early to get too up or down about it. When a large number of patients are on both drugs in high doses for an extended time then we shall see what the results are and can cry tears of joy or frustration.
 

twodogstudio2

New member
Yes I am so hopeful but that stock drop surprised me. Could the investors and financial types have misinterpreted something? From what I read they gave 770 to some people but the therapy is meant for both drugs to be used and that only happened for some in the study and only then only for one week. Seems way too early to get too up or down about it. When a large number of patients are on both drugs in high doses for an extended time then we shall see what the results are and can cry tears of joy or frustration.
 

hmw

New member
How much did sweat chloride levels drop during the same stage of the trial process w/ 770? If there was an early, much larger response in sweat chloride levels in those on 770 alone (the G551D population) is it due to comparison between the two trials that there wasn't a different response on the market? I don't know that answer off the top of my head but it was the first thing that occurred to me. I am sure the investors know all that data inside and out.
<br>
<br>Otherwise, I agree it's too soon to tell. It's a significant change after such a short period of time and the fact that their numbers reverted back to previous levels after discontinuing the meds proved they were certainly DOING something. I am excited to see what will come as the trials continue. <img src="i/expressions/face-icon-small-smile.gif" border="0">
<br>
<br>I want to know what it will do for pulmonary function, sweat test levels mean nothing without clinical response and someone with a sweat test score of 80 can be sicker than someone with a score of 120. But that is not something that could be expected to be seen in such a short trial- we need the lengthier ones for this.
 

hmw

New member
How much did sweat chloride levels drop during the same stage of the trial process w/ 770? If there was an early, much larger response in sweat chloride levels in those on 770 alone (the G551D population) is it due to comparison between the two trials that there wasn't a different response on the market? I don't know that answer off the top of my head but it was the first thing that occurred to me. I am sure the investors know all that data inside and out.
<br>
<br>Otherwise, I agree it's too soon to tell. It's a significant change after such a short period of time and the fact that their numbers reverted back to previous levels after discontinuing the meds proved they were certainly DOING something. I am excited to see what will come as the trials continue. <img src="i/expressions/face-icon-small-smile.gif" border="0">
<br>
<br>I want to know what it will do for pulmonary function, sweat test levels mean nothing without clinical response and someone with a sweat test score of 80 can be sicker than someone with a score of 120. But that is not something that could be expected to be seen in such a short trial- we need the lengthier ones for this.
 

hmw

New member
How much did sweat chloride levels drop during the same stage of the trial process w/ 770? If there was an early, much larger response in sweat chloride levels in those on 770 alone (the G551D population) is it due to comparison between the two trials that there wasn't a different response on the market? I don't know that answer off the top of my head but it was the first thing that occurred to me. I am sure the investors know all that data inside and out.
<br>
<br>Otherwise, I agree it's too soon to tell. It's a significant change after such a short period of time and the fact that their numbers reverted back to previous levels after discontinuing the meds proved they were certainly DOING something. I am excited to see what will come as the trials continue. <img src="i/expressions/face-icon-small-smile.gif" border="0">
<br>
<br>I want to know what it will do for pulmonary function, sweat test levels mean nothing without clinical response and someone with a sweat test score of 80 can be sicker than someone with a score of 120. But that is not something that could be expected to be seen in such a short trial- we need the lengthier ones for this.
 

MMBinNC

New member
It sold off because the reduction in sweat chloride, 9.91mmols, may not be enough to impact lung function
 

MMBinNC

New member
It sold off because the reduction in sweat chloride, 9.91mmols, may not be enough to impact lung function
 

MMBinNC

New member
It sold off because the reduction in sweat chloride, 9.91mmols, may not be enough to impact lung function
 

angelsmom

New member
Investors were not happy with the reduction in sweat chloride levels, which was lower than what was apparently expected.


"Vertex said the higher-dose combination therapy reduced patients' sweat chloride levels by 9.1 millimoles per liter. Citi Investment Research analyst Yaron Werber said that was less than investors were hoping for.

"The data (...) technically falls a bit lower than the 15 mmol/L reduction that the Street wanted to see," Werber said.

In a note published before the results were released, RBC Capital Markets analyst Jason Kantor wrote that a 10 mmol/L reduction would be the lowest result considered positive."

From: http://sg.news.yahoo.com/vertex-pharma-falls-cystic-fibrosis-study-data-151843622.html
 

angelsmom

New member
Investors were not happy with the reduction in sweat chloride levels, which was lower than what was apparently expected.


"Vertex said the higher-dose combination therapy reduced patients' sweat chloride levels by 9.1 millimoles per liter. Citi Investment Research analyst Yaron Werber said that was less than investors were hoping for.

"The data (...) technically falls a bit lower than the 15 mmol/L reduction that the Street wanted to see," Werber said.

In a note published before the results were released, RBC Capital Markets analyst Jason Kantor wrote that a 10 mmol/L reduction would be the lowest result considered positive."

From: http://sg.news.yahoo.com/vertex-pharma-falls-cystic-fibrosis-study-data-151843622.html
 
Top